Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
-
Published:2005-03-01
Issue:7
Volume:23
Page:1420-1430
-
ISSN:0732-183X
-
Container-title:Journal of Clinical Oncology
-
language:en
-
Short-container-title:JCO
Author:
Cristofanilli Massimo1, Hayes Daniel F.1, Budd G. Thomas1, Ellis Mathew J.1, Stopeck Alison1, Reuben James M.1, Doyle Gerald V.1, Matera Jeri1, Allard W. Jeffrey1, Miller M. Craig1, Fritsche Herbert A.1, Hortobagyi Gabriel N.1, Terstappen Leon W.M.M.1
Affiliation:
1. From The University of Texas M.D. Anderson Cancer Center, Houston, TX; The University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The Cleveland Clinic, Cleveland, OH; Washington University, St Louis, MO; University of Arizona, Phoenix, AZ; and Immunicon Corporation, Huntingdon Valley, PA
Abstract
Purpose Metastatic breast cancer (MBC) is incurable; its treatment is palliative. We investigated whether the presence of circulating tumor cells (CTCs) predicts treatment efficacy, progression-free survival (PFS), and overall survival (OS) in patients with newly diagnosed MBC who were about to start first-line therapy. Patients and Methods One hundred seventy-seven patients with measurable MBC were enrolled onto a prospective study. Eighty-three of the 177 patients were entering first-line treatment, and these patients are the focus of this analysis. CTCs from 7.5 mL of whole blood drawn before treatment initiation (baseline) and monthly thereafter for up to 6 months were isolated and enumerated using immunomagnetics. Results The mean (± standard deviation) follow-up time was 11.1 ± 4.4 months (median, 12.2 months). Forty-three patients (52%) had ≥ five CTCs at baseline. The median PFS was 7.2 months (95% CI, 4.9 to 9.4 months), and the median OS was more than 18 months. Patients with ≥ five CTCs at baseline and at first follow-up (4 weeks) had a worse prognosis than patients with less than five CTCs (baseline: median PFS, 4.9 v 9.5 months, respectively; log-rank, P = .0014; median OS, 14.2 v > 18 months, respectively; log-rank, P = .0048; first follow-up: median PFS, 2.1 v 8.9 months, respectively; log-rank, P = .0070; median OS, 11.1 v > 18 months, respectively; log-rank, P = .0029). CTCs before and after the initiation of therapy were strong, independent prognostic factors. Conclusion Detection of CTCs before initiation of first-line therapy in patients with MBC is highly predictive of PFS and OS. This technology can aid in appropriate patient stratification and design of tailored treatments.
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Reference22 articles.
1. Ellis M, Hayes DF, Lippman ME: Treatment of metastatic disease, in Harris J, Lippman M, Morrow M, et al (eds). Diseases of the Breast (ed 2) . Philadelphia, PA, Lippincott-Raven, pp 749,2000-799 2. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. 3. Nieto Y, Cagnoni PJ, Shpall EJ, et al: Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease. Clin Cancer Res 5:1731,1999-1737, 4. Fluorouracil, Doxorubicin, and Cyclophosphamide Followed by Tamoxifen as Adjuvant Treatment for Patients with Stage IV Breast Cancer with No Evidence of Disease 5. Swenerton KD, Legha SS, Smith L, et al: Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39:1552,1979-1562,
Cited by
938 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|